Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer
Abstract Background Peritoneal dissemination is the predominant feature of malignant progression in ovarian cancer and is a major cause of poor surgical outcomes and clinical prognoses. Abnormal glycosylation of carbohydrate antigen 125 (CA125) may be involved in peritoneal implantation and metastas...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-022-01066-1 |
| _version_ | 1797977317379670016 |
|---|---|
| author | Xiayu Jin Ming Du Yisheng Wang Yuefei Wang Yingying Lu Congjian Xu Xiaoyan Zhang |
| author_facet | Xiayu Jin Ming Du Yisheng Wang Yuefei Wang Yingying Lu Congjian Xu Xiaoyan Zhang |
| author_sort | Xiayu Jin |
| collection | DOAJ |
| description | Abstract Background Peritoneal dissemination is the predominant feature of malignant progression in ovarian cancer and is a major cause of poor surgical outcomes and clinical prognoses. Abnormal glycosylation of carbohydrate antigen 125 (CA125) may be involved in peritoneal implantation and metastasis. Here, we evaluated the clinical relevance of CA125-Tn glycoform in the assessment of high-grade serous ovarian cancer (HGSOC). Methods A total of 72 patients diagnosed with HGSOC were included. Pre-treatment serum CA125-Tn levels were measured using an antibody-lectin enzyme-linked immunosorbent assay. The association of CA125-Tn with clinical factors was analyzed in all cases, whereas its association with peritoneal dissemination, residual disease, and progression-free survival was analyzed in stage III–IV cases. Results Pre-treatment serum CA125-Tn levels were significantly higher in advanced-stage HGSOC patients than in early-stage patients (P = 0.029). In advanced-stage patients, the pre-treatment CA125-Tn level increased with an increase in Fagotti’s score (P = 0.004) and with the extension of peritoneal dissemination (P = 0.011). The pre-treatment CA125-Tn level increased with the volume of residual disease (P = 0.005). The association between CA125-Tn level and suboptimal surgery remained significant even after adjustment for treatment type and stage. Pre-treatment CA125-Tn levels were also related to disease recurrence. Conclusion Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator. |
| first_indexed | 2024-04-11T05:04:55Z |
| format | Article |
| id | doaj.art-0fc09bbce904474ab3badc1a1d1ab00d |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T05:04:55Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-0fc09bbce904474ab3badc1a1d1ab00d2022-12-25T12:25:38ZengBMCJournal of Ovarian Research1757-22152022-12-011511910.1186/s13048-022-01066-1Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancerXiayu Jin0Ming Du1Yisheng Wang2Yuefei Wang3Yingying Lu4Congjian Xu5Xiaoyan Zhang6Obstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityObstetrics and Gynecology Hospital, Fudan UniversityAbstract Background Peritoneal dissemination is the predominant feature of malignant progression in ovarian cancer and is a major cause of poor surgical outcomes and clinical prognoses. Abnormal glycosylation of carbohydrate antigen 125 (CA125) may be involved in peritoneal implantation and metastasis. Here, we evaluated the clinical relevance of CA125-Tn glycoform in the assessment of high-grade serous ovarian cancer (HGSOC). Methods A total of 72 patients diagnosed with HGSOC were included. Pre-treatment serum CA125-Tn levels were measured using an antibody-lectin enzyme-linked immunosorbent assay. The association of CA125-Tn with clinical factors was analyzed in all cases, whereas its association with peritoneal dissemination, residual disease, and progression-free survival was analyzed in stage III–IV cases. Results Pre-treatment serum CA125-Tn levels were significantly higher in advanced-stage HGSOC patients than in early-stage patients (P = 0.029). In advanced-stage patients, the pre-treatment CA125-Tn level increased with an increase in Fagotti’s score (P = 0.004) and with the extension of peritoneal dissemination (P = 0.011). The pre-treatment CA125-Tn level increased with the volume of residual disease (P = 0.005). The association between CA125-Tn level and suboptimal surgery remained significant even after adjustment for treatment type and stage. Pre-treatment CA125-Tn levels were also related to disease recurrence. Conclusion Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator.https://doi.org/10.1186/s13048-022-01066-1Ovarian cancerCA125Tn antigenCytoreductive surgeryPeritoneal disseminationResidual disease |
| spellingShingle | Xiayu Jin Ming Du Yisheng Wang Yuefei Wang Yingying Lu Congjian Xu Xiaoyan Zhang Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer Journal of Ovarian Research Ovarian cancer CA125 Tn antigen Cytoreductive surgery Peritoneal dissemination Residual disease |
| title | Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer |
| title_full | Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer |
| title_fullStr | Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer |
| title_full_unstemmed | Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer |
| title_short | Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer |
| title_sort | evaluation of serum ca125 tn glycoform in peritoneal dissemination and surgical completeness of high grade serous ovarian cancer |
| topic | Ovarian cancer CA125 Tn antigen Cytoreductive surgery Peritoneal dissemination Residual disease |
| url | https://doi.org/10.1186/s13048-022-01066-1 |
| work_keys_str_mv | AT xiayujin evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT mingdu evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT yishengwang evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT yuefeiwang evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT yingyinglu evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT congjianxu evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer AT xiaoyanzhang evaluationofserumca125tnglycoforminperitonealdisseminationandsurgicalcompletenessofhighgradeserousovariancancer |